Schonfeld Strategic Advisors’s Ovid Therapeutics OVID Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$471K	Buy	212,211 +19,715	+10%	+$35.2K	﹤0.01%	1409
2025 Q4	$314K	Sell	192,496 -690,658	-78%	-$1.06M	﹤0.01%	1564
2025 Q3	$1.15M	Buy	+883,154	New	+$765K	0.01%	1303
2021 Q4	–	Sell	-10,100	Closed	-$34K	–	2428
2021 Q3	$34K	Buy	+10,100	New	+$36.8K	﹤0.01%	2020
2021 Q2	–	Sell	-64,000	Closed	-$257K	–	2203
2021 Q1	$257K	Buy	+64,000	New	+$213K	﹤0.01%	1393
2018 Q2	–	Sell	-20,520	Closed	-$145K	–	912
2018 Q1	$145K	Hold	20,520	–	–	0.01%	700
2017 Q4	$203K	Sell	20,520 -12,980	-39%	-$119K	0.02%	672
2017 Q3	$287K	Sell	33,500 -1,500	-4%	-$12.5K	0.03%	460
2017 Q2	$367K	Buy	+35,000	New	+$457K	0.04%	443

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Schonfeld Strategic Advisors's OVID Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Ovid Therapeutics (OVID) stake by 10% in Q1 2026, buying an estimated $35.2K and bringing the position to 212,211 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Schonfeld Strategic Advisors first reported a position in OVID in Q2 2017 and has held it in 9 quarters since. The position peaked at $1.15M in Q3 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Schonfeld Strategic Advisors held 212,211 shares of Ovid Therapeutics worth $471K as of Q1 2026.
Schonfeld Strategic Advisors bought 19,715 Ovid Therapeutics shares in Q1 2026, an estimated $35.2K.
Ovid Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1409 holding.
Schonfeld Strategic Advisors first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 9 quarters since.
Schonfeld Strategic Advisors's Ovid Therapeutics position peaked at $1.15M in Q3 2025.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.